

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



The following tables provide guidance for COVID-19 vaccination schedules based on age and medical condition and vaccine composition.

Table 1a. **Moderna: Immunization Schedule for Children 6 Months through 17 Years of Age**

Age*	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
	Doses	Interval Between Doses†	Doses	Interval Between Doses
6 months through 5 years	Primary series‡: MONOVALENT VACCINE (Blue capped vial with magenta-bordered label)			
	Dose 1 to 2	At least 4–8 weeks [§]	Dose 1 to 2	At least 4 weeks
			Dose 2 to 3	At least 4 weeks
	Booster dose¶ **: BIVALENT VACCINE (Dark pink capped vial with yellow-bordered label)			
Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
6 through 11 years	Primary series†† : MONOVALENT VACCINE (Blue capped vial with purple-bordered label)			
	Dose 1 to 2	At least 4–8 weeks [§]	Dose 1 to 2	At least 4 weeks
			Dose 2 to 3	At least 4 weeks
	Booster dose: BIVALENT VACCINE (Blue capped vial with gray-bordered label)			
Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
12 through 17 years	Primary series** : MONOVALENT VACCINE (Red capped vial with blue-bordered label)			
	Dose 1 to 2	At least 4–8 weeks [§]	Dose 1 to 2	At least 4 weeks
			Dose 2 to 3	At least 4 weeks
	Booster dose: BIVALENT VACCINE (Blue capped vial with gray-bordered label)			
Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	

* Guidance related to special situations when vaccinating children, such as those who have a birthday before completing the primary series or booster dose, see [Special Situations for COVID-19 Vaccination of Children and Adolescents](#)

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Complete primary series with the same manufacturer's product. If the previously administered products are unknown, not available, [contraindicated](#) or a mixed manufacturer-product series (Pfizer-BioNTech and Moderna vaccines), follow a 3-dose schedule. A third dose of either a monovalent Moderna vaccine or a bivalent Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose to complete the primary series.

§ An 8-week interval between the first and second primary series doses of COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. The authorized interval (4 weeks for Moderna COVID-19 Vaccine) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

¶ Children ages 6 months–4 years who received a 3-dose mixed-manufacturer (Moderna and Pfizer-BioNTech) primary series:

- With any combination of monovalent Moderna and monovalent Pfizer-BioNTech vaccines, should receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the primary series.
- With a bivalent Pfizer-BioNTech vaccine as the third primary series dose, should receive 1 bivalent Pfizer-BioNTech booster dose when they turn age 5 years and at least 2 months after completion of the primary series.

** Children 5 years of age who completed a primary series of Moderna COVID-19 Vaccine, may receive either bivalent Moderna or Pfizer-BioNTech COVID-19 vaccine for the booster dose.

†† Complete the primary series with same manufacturer's product. If the vaccine product previously administered are unknown, no longer available, or [contraindicated](#), complete a 2-dose series with a monovalent mRNA vaccine at least 28 days (4 weeks) between Dose 1 and 2. Administer bivalent mRNA COVID-19 vaccine at least 8 weeks (2 months) after Dose 2.

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule for Persons 6 Months of Age and Older



Table 1b. **Pfizer-BioNTech: Immunization Schedule for Children 6 Months through 17 Years of Age**

Age*	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
	Doses	Interval Between Doses†	Doses	Interval Between Doses
6 months through 4 years	Primary series‡: MONOVALENT VACCINE - Doses 1 and 2 (Maroon capped vial with maroon-bordered label) and BIVALENT VACCINE - Dose 3 (Maroon capped vial with maroon-bordered label)			
	Dose 1 to 2	At least 3–8 weeks [§]	Dose 1 to 2	At least 3 weeks
	Doses 2 and 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks
	Booster dose:¶ BIVALENT VACCINE (Maroon capped vial with maroon-bordered label) Children who previously received a 3-dose series of monovalent Pfizer-BioNTech Vaccine: Administer 1 dose of bivalent vaccine at least 8 weeks (2 months) after the previous dose.			
5 through 11 years	Primary series**: MONOVALENT VACCINE (Orange capped vial with orange-bordered label)			
	Dose 1 to 2	At least 3–8 weeks [§]	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 4 weeks
	Booster dose: BIVALENT VACCINE (Orange capped vial with orange-bordered label)			
Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	
12 years through 17 years	Primary series**: MONOVALENT VACCINE (Gray capped vial with gray-bordered label)			
	Dose 1 to 2	At least 3–8 weeks [§]	Dose 1 to 2	At least 3 weeks
			Dose 2 to 3	At least 4 weeks
	Booster dose: BIVALENT VACCINE (Gray capped vial with gray-bordered label)			
Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)	

* Guidance related to special situations when vaccinating children, such as those who have a birthday before completing the primary series or booster dose, see [Special Situations for COVID-19 Vaccination of Children and Adolescents](#)

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Complete primary series with the same manufacturer's product. If the previously administered products are unknown, not available, [contraindicated](#) or a mixed manufacturer-product series (Pfizer-BioNTech and Moderna vaccines), follow a 3-dose schedule. A third dose of either a monovalent Moderna vaccine or a bivalent Pfizer-BioNTech vaccine should be administered at least 8 weeks after the second dose to complete the primary series.

§ An 8-week interval between the first and second primary series doses of COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with these vaccines. The authorized interval (3 weeks for Pfizer-BioNTech COVID-19 vaccine) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

¶ Children ages 6 months–4 years who received a mixed-manufacturer (Moderna and Pfizer-BioNTech) 3-dose primary series:

- With any combination of monovalent Moderna and monovalent Pfizer-BioNTech vaccines should receive 1 bivalent Pfizer-BioNTech booster dose at least 2 months after completion of the primary series.
- With a bivalent Pfizer-BioNTech vaccine as the third primary series dose should receive 1 bivalent Pfizer-BioNTech booster dose when they turn age 5 years and at least 2 months after completion of the primary series.

** Complete the primary series with same manufacturer's product. If the previously administered products are unknown, not available, [contraindicated](#) or a mixed manufacturer-product series (Pfizer-BioNTech and Moderna vaccines), complete a 2-dose series with a monovalent mRNA vaccine at least 28 days (4 weeks) between Dose 1 and 2. Administer bivalent mRNA COVID-19 vaccine at least 8 weeks (2 months) after Dose 2.

CDC Resources

[CDC COVID-19 vaccine clinical training and materials](#)

[CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)

[CDC Vaccine administration clinical materials](#)

[CDC Vaccine Storage and Handling Toolkit](#)

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 1c. **Novavax: Immunization Schedule for Children 6 Months through 17 Years of Age**

Age*	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
	Doses	Interval Between Doses†	Doses	Interval Between Doses
12 years and older	Primary series‡: MONOVALENT VACCINE			
	Dose 1 to 2	At least 3–8 weeks§	Dose 1 to 2	At least 3 weeks
	Booster dose: BIVALENT mRNA VACCINE Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.			
	Dose 2 to 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks (2 months)

* Guidance related to special situations when vaccinating children, such as those who have a birthday before completing the primary series or booster dose, see [Special Situations for COVID-19 Vaccination of Children and Adolescents](#)

† Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

‡ Complete the primary series with same manufacturer's product. If the vaccine product previously administered cannot be determined or is no longer available, complete a 2-dose series with a monovalent vaccine at least 28 days (4 weeks) between Dose 1 and 2. Administer bivalent mRNA COVID-19 vaccine at least 8 weeks (2 months) after Dose 2.

§ An 8-week interval between the first and second primary series doses of COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with COVID-19 vaccines. The authorized interval (3 weeks for Novavax COVID-19 vaccine) between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

CDC Resources

[CDC COVID-19 vaccine clinical training and materials](#)

[CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)

[CDC Vaccine administration clinical materials](#)

[CDC Vaccine Storage and Handling Toolkit](#)

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 2. Immunization Schedule for Persons 18 Years of Age

Type	Age	For Most People		Those Who ARE Moderately or Severely Immunocompromised	
		Doses	Interval Between Doses*	Doses	Interval Between Doses
Moderna	18 years and older	Primary series[†]: MONOVALENT VACCINE (Red capped vial with a blue-bordered label)			
		Dose 1 to 2	At least 4–8 weeks [‡]	Dose 1 to 2	At least 4 weeks
				Dose 2 to 3	At least 4 weeks
		Booster dose[§]: BIVALENT VACCINE (Blue capped vial with a gray-bordered label)			
		Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)
Pfizer-BioNTech	18 years and older	Primary series[†]: MONOVALENT VACCINE (Gray capped vial with a gray-bordered label)			
		Dose 1 to 2	At least 3-8 weeks [‡]	Dose 1 to 2	At least 3 weeks
				Dose 2 to 3	At least 4 weeks
		Booster dose[§]: BIVALENT VACCINE (Gray capped vial with a gray-bordered label)			
		Dose 2 to 3	At least 8 weeks (2 months)	Dose 3 to 4	At least 8 weeks (2 months)
Novavax	18 years and older	Primary series[†]: MONOVALENT VACCINE			
		Dose 1 to 2	At least 3–8 weeks [‡]	Dose 1 to 2	At least 3 weeks
		Booster dose[§]: BIVALENT VACCINE Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.			
		Dose 2 to 3	At least 8 weeks (2 months)	Dose 2 to 3	At least 8 weeks (2 months)
Janssen	18 years and older	Primary series: MONOVALENT VACCINE Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations. [¶]			
		Booster dose[§]: BIVALENT mRNA VACCINE Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine should be used for the booster dose.			
		Administer a single booster dose at least 8 weeks (2 months) after the previous dose.			

* Persons with a recent SARS-CoV-2 infection may consider delaying a primary series or booster dose by 3 months from symptom onset or positive test (if infection was asymptomatic).

† Complete the primary series with same product. If the vaccine product previously administered cannot be determined, is no longer available or contraindicated, any age-appropriate monovalent COVID-19 vaccine may be administered at least 28 days after the first dose to complete the primary series. Moderna or Pfizer-BioNTech bivalent COVID-19 vaccine can be administered for the booster dose, regardless of the primary series product.

‡ An 8-week interval between the first and second primary series doses of COVID-19 vaccines may be optimal for some people ages 6 months–64 years, especially for males ages 12–39 years, as it may reduce the small risk of myocarditis and pericarditis associated with COVID-19 vaccines. A shorter interval between the first and second doses remains the recommended interval for people who are moderately or severely immunocompromised; adults ages 65 years and older; and in situations in which there is increased concern about COVID-19 community levels or an individual's higher risk of severe disease.

§ A single Novavax booster dose (instead of a bivalent mRNA booster dose) may be given to persons 18 years of age or older who have not received a previous booster dose in **limited situations**. These situations are 1. an mRNA vaccine is contraindicated, or not available or 2. the recipient is unwilling to receive an mRNA vaccine and would otherwise not receive a booster dose. Administer the booster dose at least 6 months after the last primary series dose.

¶ For guidance on use of Janssen vaccine and retrospective record review, scheduling and administration see [Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A](#).

CDC Resources

[CDC COVID-19 vaccine clinical training and materials](#)

[CDC Interim Clinical Considerations for the Use of COVID-19 Vaccines Currently Approved or Authorized in the United States](#)

[CDC Vaccine administration clinical materials](#)

[CDC Vaccine Storage and Handling Toolkit](#)

COVID-19 Vaccine

Interim COVID-19 Immunization Schedule
for Persons 6 Months of Age and Older



Table 3. COVID-19 Vaccine Products Summary*

Type	Product	Age Indications [†]	Diluent	Use For: [‡]	Dose/Injection Amount	
mRNA vaccine	MONOVALENT Moderna: Blue capped vial with magenta-bordered label	6 months through 5 years	NONE	Any dose in the primary series	25 µg/ 0.25 mL	
	BIVALENT Moderna: Dark pink capped vial with yellow-bordered label	6 months through 5 years	NONE	Booster dose	10 µg/ 0.2 mL	
	MONOVALENT Moderna: Blue capped vial with purple-bordered label	6 through 11 years	NONE	Any dose in the primary series	50 µg/0.5 mL	
	BIVALENT Moderna: Blue capped vial with gray-bordered label	6 through 11 years	NONE	Booster dose	25 µg/0.25 mL	
	MONOVALENT Moderna: Red capped vial with blue- bordered label	12 years and older	NONE	Any dose in the primary series	100 µg/ 0.5 mL	
	BIVALENT Moderna: Blue capped vial with gray-bordered label	12 years and older	NONE	Booster dose	50 µg/0.5 mL	
	MONOVALENT Pfizer-BioNTech: Maroon capped vial with maroon-bordered label	6 months through 4 years	2.2 mL 0.9% sodium chloride (normal saline, preservative-free)	Primary series Doses 1 and 2	3 µg/0.2 mL	
	BIVALENT Pfizer-BioNTech: Maroon capped vial with maroon-bordered label	6 months through 4 years	2.2 mL 0.9% sodium chloride (normal saline, preservative-free)	Primary series Dose 3 or Booster Dose	3 µg/0.2 mL	
	MONOVALENT Pfizer-BioNTech: Orange capped vial with orange-bordered label	5 through 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Any dose in the primary series	10 µg/0.2 mL	
	BIVALENT Pfizer-BioNTech: Orange capped vial with a orange-bordered label	5 through 11 years	1.3 mL 0.9% sodium chloride (normal saline, preservative-free)	Booster dose	10 µg/0.2 mL	
	MONOVALENT Pfizer-BioNTech: Gray capped vial with a gray- bordered label	12 years and older	NONE	Any dose in the primary series	30 µg/0.3 mL	
	BIVALENT Pfizer-BioNTech: Gray capped vial with gray-bordered label Single-dose Vials and Multidose Vials	12 years and older	NONE	Booster dose	30 µg/0.3 mL	
	Protein sub unit vaccine	MONOVALENT Novavax: Royal blue capped vial	12 years and older	NONE	Any dose in the primary series or as a single booster dose, in limited situations , for persons 18 years of age or older	5 µg rS and 50 µg of Matrix-M™ adjuvant/0.5 mL
	Viral vector vaccine	MONOVALENT Janssen: Blue capped vial	18 years and older	NONE	Janssen COVID-19 vaccine is authorized for use in certain limited situations due to safety considerations [§]	5×10 ¹⁰ viral particles/0.5 mL

* **NOTE:** Some COVID-19 monovalent vaccine products are expired or expiring soon. Healthcare professionals should: Always check expiration dates prior to administration. **NEVER administer expired vaccine.** CDC recommends providers check vaccine expiration dates weekly, remove expired vaccine from the storage unit and discard, according to the manufacturer's, federal and state requirements, and document the wastage. Other COVID-19 vaccine products are available for those persons seeking vaccination and who have not completed a primary series, see [Clinical Guidance for COVID-19 Vaccination | CDC](#)

[†] Administer the appropriate vaccine product based on the recipient's age and the vaccine product's indications.

[‡] COVID-19 vaccines may be administered on the same day as other routinely recommended vaccines, including influenza vaccine.

[§] For guidance on use of Janssen vaccine and retrospective record review, scheduling and administration see [Interim Clinical Considerations for Use of COVID-19 Vaccines: Appendix A](#)